Private Securities Litigation Reform Act of 1995

This website and the documents incorporated herein by reference contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about the industry and markets in which Enzo Life Sciences operates, as well as management's beliefs and assumptions.

Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," "would," and similar expressions. These statements are not guarantees of future performance and involve certain risks, uncertainties, and assumptions that are difficult to predict.

Risks and Uncertainties

Actual results may differ materially from those expressed or implied in forward-looking statements due to various factors, including but not limited to:

• Changes in general economic and business conditions
• Changes in technology and market requirements
• The ability to attract and retain qualified personnel
• The ability to develop and commercialize new products
• Regulatory changes affecting the life sciences industry
• Competition from other life sciences companies
• Fluctuations in foreign currency exchange rates
• The impact of geopolitical events and public health crises
• Changes in tax laws and regulations
• The outcome of pending and future litigation

Enzo Life Sciences undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Investor Relations

Investors and security holders are urged to read any documents filed with the U.S. Securities and Exchange Commission (SEC), including periodic reports on Forms 10-K, 10-Q, and 8-K, as well as proxy statements and other information filed or furnished by the Company.

For more information about Enzo Life Sciences and its financial disclosures, please visit the SEC's EDGAR database or contact our Investor Relations department.